A5046758725- Breast Cancer Treatment Studies
- Breast Lesions and Carcinomas
- Ovarian cancer diagnosis and treatment
- Cancer Treatment and Pharmacology
- Cancer Genomics and Diagnostics
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Multiple Myeloma Research and Treatments
- Endometrial and Cervical Cancer Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer and Skin Lesions
- BRCA gene mutations in cancer
- Cancer Risks and Factors
- Renal cell carcinoma treatment
- PARP inhibition in cancer therapy
- Chemotherapy-induced cardiotoxicity and mitigation
- Lung Cancer Treatments and Mutations
- Intraperitoneal and Appendiceal Malignancies
- Global Cancer Incidence and Screening
- Cancer-related Molecular Pathways
- AI in cancer detection
- Cancer Cells and Metastasis
- Peptidase Inhibition and Analysis
- Angiogenesis and VEGF in Cancer
- Sarcoma Diagnosis and Treatment
Alexandra Hospital
2016-2025
National and Kapodistrian University of Athens
2016-2025
Hellenic Cooperative Oncology Group
2014-2024
Hellenic Oncology Research Group
2023
Athens City
2022
Frontier Science Foundation-Hellas
2020
National Centre of Scientific Research "Demokritos"
2020
Therapeutics Clinical Research
2011-2019
Hippocration General Hospital
2008-2019
Senologic Hellenic Society
2019
Among breast cancers without human epidermal growth factor receptor 2 (HER2) amplification, overexpression, or both, a large proportion express low levels of HER2 that may be targetable. Currently available HER2-directed therapies have been ineffective in patients with these "HER2-low" cancers.
In monarchE, abemaciclib plus endocrine therapy (ET) as adjuvant treatment of hormone receptor-positive, human epidermal growth factor 2-negative, high-risk, early breast cancer (EBC) demonstrated a clinically meaningful improvement in invasive disease-free survival versus ET alone. Detailed safety analyses conducted at median follow-up 27 months and key patient-reported outcomes (PROs) are presented.The population included all patients who received least one dose study (n = 5591). Safety...
Plasma cell‐free DNA (cfDNA) analysis to track estrogen receptor 1 ( ESR1 ) mutations is highly beneficial for the identification of tumor molecular dynamics and improvement personalized treatments patients with metastatic breast cancer (MBC). Plasma‐cfDNA is, up now, most frequent liquid biopsy analyte used evaluate mutational status. Circulating cell (CTC) enumeration characterization provides important clinical information in MBC. In this study, we investigated whether CTCs circulating...
Purpose To evaluate the apparent diffusion coefficients (ADCs) of magnetic resonance (MR) imaging patterns in bone marrow patients with multiple myeloma (MM) and to determine a threshold ADC that may help distinguish diffuse from normal pattern high accuracy. Materials Methods This prospective study was approved by ethics review board, informed consent obtained. Ninety-nine newly diagnosed, untreated MM 16 healthy control subjects underwent spinal MR including diffusion-weighted imaging,...
PURPOSE Selinexor inhibits exportin-1 (XPO1) resulting in nuclear accumulation of tumor suppressor proteins including p53 and has clinical activity endometrial cancer (EC). The primary end point was to assess progression-free survival (PFS) with once-weekly oral selinexor patients advanced or recurrent EC. PATIENTS AND METHODS ENGOT-EN5/GOG-3055/SIENDO a randomized, prospective, multicenter, double-blind, placebo-controlled, phase III study at 107 sites 10 countries. Patients 18 years older...
Abstract Background Recent evidence suggests that neutrophil gelatinase-associated lipocalin (NGAL) expression is induced in many types of human cancer, while detection its complex with matrix metalloproteinase-9 (MMP-9) correlated cancer disease status. We aim to evaluate the serum MMP-9, NGAL and their (MMP-9/NGAL) during diagnostic work-up women breast abnormalities investigate correlation severity. Methods The study included 113 non-palpable lesions undergoing vacuum-assisted biopsy for...
The mesenchymal–epithelial transition (MET) pathway is frequently altered in tumours. purpose of our study was to determine the prognostic value tumour MET expression levels patients with triple-negative breast cancer (TNBC), order strengthen rationale for targeted therapy TNBC using inhibitors. We determined formalin-fixed paraffin-embedded surgical specimens by immunohistochemistry. Recurrence-free and overall survival analysed Cox models adjusted clinical pathological factors....